You are here

FDA Panel Recommends Approval of Degludec Insulin

Cardiovascular outcomes trial will be required (Nov. 9)

The FDA has completed its advisory committee meeting regarding the New Drug Applications (NDAs) for insulin degludec and insulin degludec/insulin aspart (Novo Nordisk).

At the meeting, the committee was asked to discuss the data contained in the NDAs and in subsequent submissions regarding the benefits associated with a lower risk of hypoglycemia and the cardiovascular risk profiles of the two products.

The FDA asked the panel members to vote on whether a cardiovascular outcomes trial should be conducted and on whether sufficient safety and efficacy data had been provided to support marketing of insulin degludec and insulin degludec/insulin aspart.

The committee unanimously recommended that a cardiovascular outcomes trial should be conducted and voted 8 to 4 in favor of approving the products with a post-approval outcomes trial commitment.

The agency has not announced when it expects to complete its review of the NDAs.

Source: Novo Nordisk; November 9, 2012.

Recent Headlines

Almost 64% of Patients Showed Decreased Hemoglobin A1c Levels
Lifesaving Life Foam for Battlefield, Terrorist Attacks, Trauma
Cell Reprogramming Process May Benefit Patients Prone to Severe Hypoglycemia
Beagles Beat Out Advanced Technology
Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
Over 25% of Study Patients Showed 6–12 Months Remission